A Phase 3 interventional study of Finerenone and Placebo in Chronic Kidney Disease and Type 1 Diabetes Mellitus, sponsored by Bayer. Completed at 79 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing finerenone in Renal Insufficiency, Chronic — 14 open to participants now, 16 under way, 4 of them phase 3. finerenone · Renal Insufficiency, Chronic.
Among the 25 studies testing finerenone in Renal Insufficiency, Chronic, this one is the 6th largest by enrollment, is one of 5 that started in 2024, is one of 6 in phase 3, and was the 9th registered.
3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.
Browse Renal Insufficiency, Chronic studies →14 of the 25 studies testing finerenone in Renal Insufficiency, Chronic are open now, in 12 countries. Recruiting first, the newest first:
Peter Rossing · Sites in Denmark, Germany, Spain and 1 more country
Ages 18–75
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18+
University of Aarhus · Sites in Denmark
Ages 18+
The George Institute · Sites in Australia, India, New Zealand and 2 more countries
Ages 18+
Bayer · Sites in United States, Argentina, Australia and 29 more countries
Ages 1–18
By country, each count listing its studies:
finerenone: first FDA approval 2021 (KERENDIA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 242 is above the median of 73 across 2,162 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 100 across the 25 interventional studies. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 25 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
49 studies in Renal Insufficiency, Chronic by Bayer: 4 open now, 8 under way, 2 of them phase 3. Of 39 finished, 4 (10%) have results posted.
Among the 49 studies in Renal Insufficiency, Chronic by Bayer, this one is the 6th largest by enrollment of the 32 interventional ones that give a count, is one of 7 that started in 2024, is one of 9 in phase 3, and was the 35th registered.
Bayer’s Renal Insufficiency, Chronic studies by the year they started, since 2009.
6 of the studies testing finerenone in Renal Insufficiency, Chronic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05196035Phase 3BayerA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | 2027-04-10 |
| NCT07235891Alexandria UniversityRetinal Protective Effects of Novel Finerenone in Patients With Chronic Kidney Disease | 2026-12-20 |
| NCT07026539University of AarhusEffect of Treatment With Finerenone on Cardio-Renal Target Organ Damage in Patients With Type 2 Diabetes. | 2026-12-31 |
| NCT07849348Peking University People's HospitalStudy on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-Diabetic Adult Patients With Obesity Complicated by Chronic Kidney Disease With Albuminuria | 2027-02 |
| NCT07155694Washington D.C. Veterans Affairs Medical CenterRole of Finerenone in African American Veterans With Diabetic Kidney Disease | 2027-07 |
Add all 6 to your calendar (.ics) → With an account.
Among the 25 studies testing finerenone in Renal Insufficiency, Chronic, from their registry updates:
Among Bayer’s 49 in Renal Insufficiency, Chronic:
This tab as a report to print or save as PDF → With an account.
Researchers are looking for a better way to treat people with chronic kidney disease (CKD), a progressive decrease in the kidneys' ability to work properly, and type 1 diabetes.
In people with type 1 diabetes, the body does not make enough of a hormone called insulin, resulting in high blood sugar levels that can cause damage to the kidneys. CKD often occurs together with or as a consequence of type 1 diabetes.
The study treatment finerenone works by blocking certain proteins, called mineralocorticoid receptors. An increased stimulation of these proteins is thought to damage the kidneys and the heart. By lowering their stimulation, finerenone reduces the risk of kidney disease progressively getting worse. Finerenone is approved for doctors to prescribe to people with CKD and type 2 diabetes.
In this study, researchers want to learn if finerenone works better than placebo in reducing the participants' kidney disease from getting worse when given in addition to standard of care (SOC) treatment. A placebo looks like a treatment but does not have any medicine in it. SOC is a procedure or treatment that medical experts consider most appropriate for a condition or disease. To find out how well finerenone works, the level of a protein (albumin) in the urine will be measured.
Researchers also want to know how safe finerenone is. To do this, the researchers will collect the number of participants with:
The participants will be in the study for up to 7.5 months and will take the study treatments for 6 months. During the study, they will visit the study site at least 6 times.
The study team will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants with Type 1 diabetes (T1D), i.e. T1D continuously treated with insulin, started within one year from diagnosis.
If the onset was after age 35, documentation of the presence of one or more of the following:
at Screening \<10% (central assessment).
Participants with a clinical diagnosis of CKD and fulfilling both the criteria (central assessment):
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with eGFR ≥25 to \<60 mL/min/1.73 m\^2 at Screening visit will take Finerenone Dose A. Participants with eGFR ≥60 mL/min/1.73 m\^2 at Screening visit will take Dose B. Up-titration and down-titration of study intervention will be based on local potassium and kidney function (eGFR) values. Treatment duration is 6 months.
Drug: Finerenone
Participants will take Finerenone matching placebo for 6 months.
Other: Placebo
Dose A, Dose B, oral
Oral
Change in UACR From Baseline (Ratio to Baseline) Over 6 Months
UACR was assessed by a central laboratory at baseline, Month 3, and Month 6. The primary efficacy variable was change in UACR from baseline over 6 months, which was evaluated on the average of the Month 3 and Month 6 geometric mean UACR ratios to baseline within each treatment arm. A ratio to baseline below 1 indicates a reduction in UACR, with a smaller value indicating a better outcome. Both values were used to assess the treatment effect, with a ratio finerenone-versus-placebo below 1 indicating a better outcome with finerenone relative to placebo.
Time frame: From baseline to Month 6
Number of Participants With Treatment-emergent AEs (TEAEs), Treatment-emergent SAEs (TESAEs)
AE: An adverse event (AE) in this study is defined as any medical problem that the participants had during the study. This includes any new medical issue or a worsening of an existing condition that happens after the participant receives the study treatment, regardless of whether it is considered related to the study treatment. AEs that started or worsened after the first dose of study intervention up to 3 days after any temporary or permanent interruption of study intervention were considered as TEAEs; for the targeted AE reporting, non-serious AEs were not mandatory to be collected.
Time frame: From the first dose of study intervention and up to 3 days after the last dose of study intervention, with a median treatment duration 6.07 months.
Number of Participants With Treatment-emergent Hyperkalaemia
Hyperkalemia (evaluated as the combined MedDRA Preferred terms blood potassium increased and hyperkalaemia) was an adverse event of special interest in this study and collected in the electronic case report form (eCRF).
Time frame: From the first dose of study intervention and up to 3 days after the last dose of study intervention, with a median treatment duration 6.07 months.
79 recruiting centers, enrolling participants across Asia, Europe, and North America
| Milestone | Finerenone Group | Placebo Group |
|---|---|---|
| Started | 120 | 122 |
| Received treatment | 119 | 122 |
| Completed | 117 | 112 |
| Not completed | 3 | 10 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Death | 0 | 2 |
| Withdrew: Participant decision | 0 | 4 |
| Withdrew: Non-compliance with study schedule | 0 | 1 |
| Withdrew: Protocol-specified withdrawal criterion met | 0 | 1 |
UACR was assessed by a central laboratory at baseline, Month 3, and Month 6. The primary efficacy variable was change in UACR from baseline over 6 months, which was evaluated on the average of the Month 3 and Month 6 geometric mean UACR ratios to baseline within each treatment arm. A ratio to baseline below 1 indicates a reduction in UACR, with a smaller value indicating a better outcome. Both values were used to assess the treatment effect, with a ratio finerenone-versus-placebo below 1 indicating a better outcome with finerenone relative to placebo.
| ratio to Baseline | Finerenone Group | Placebo Group |
|---|---|---|
| Change in UACR From Baseline (Ratio to Baseline) Over 6 Months | 0.66 (0.60 to 0.73) | 0.88 (0.79 to 0.98) |
AE: An adverse event (AE) in this study is defined as any medical problem that the participants had during the study. This includes any new medical issue or a worsening of an existing condition that happens after the participant receives the study treatment, regardless of whether it is considered related to the study treatment. AEs that started or worsened after the first dose of study intervention up to 3 days after any temporary or permanent interruption of study intervention were considered as TEAEs; for the targeted AE reporting, non-serious AEs were not mandatory to be collected.
| Participants | Finerenone Group | Placebo Group |
|---|---|---|
| Treatment-emergent AE | 56 | 60 |
| Treatment-emergent SAE | 14 | 14 |
Hyperkalemia (evaluated as the combined MedDRA Preferred terms blood potassium increased and hyperkalaemia) was an adverse event of special interest in this study and collected in the electronic case report form (eCRF).
| Participants | Finerenone Group | Placebo Group |
|---|---|---|
| Number of Participants With Treatment-emergent Hyperkalaemia | 12 | 4 |
Collected over TEAEs were collected from first dose up to 3 days after last dose of study intervention. The median treatment duration was 6.07 month. For all-cause mortality, deaths were collected from start of study (Informed consent signed) until last visit, over a median study duration of 7.11 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 2/122 (1.6%) | 14/122 (11.5%) | 3/122 (2.5%) |
| Finerenone | 0/119 (0%) | 14/119 (11.8%) | 10/119 (8.4%) |
| Event | Placebo | Finerenone |
|---|---|---|
| Diabetic ketoacidosisMetabolism and nutrition disorders | 3/122 | 2/119 |
| HypoglycaemiaMetabolism and nutrition disorders | 3/122 | 1/119 |
| Diabetes mellitus inadequate controlMetabolism and nutrition disorders | 0/122 | 2/119 |
| HyperkalaemiaMetabolism and nutrition disorders | 0/122 | 2/119 |
| Acute kidney injuryRenal and urinary disorders | 0/122 | 2/119 |
| Atrial fibrillationCardiac disorders | 0/122 | 1/119 |
| Cardiac failureCardiac disorders | 0/122 | 1/119 |
| Myocardial ischaemiaCardiac disorders | 1/122 | 1/119 |
| Acute coronary syndromeCardiac disorders | 0/122 | 1/119 |
| Diabetic retinopathyEye disorders | 0/122 | 1/119 |
| Event | Placebo | Finerenone |
|---|---|---|
| HyperkalaemiaMetabolism and nutrition disorders | 3/122 | 10/119 |
| Age, Continuous(years) | Finerenone Group | Placebo Group | Total |
|---|---|---|---|
| Mean | 51.25 ± 14.17 | 51.88 ± 23.20 | 51.57 ± 13.69 |
| Sex: Female, Male(Participants) | Finerenone Group | Placebo Group | Total |
|---|---|---|---|
| Female | 41 | 43 | 84 |
| Male | 79 | 79 | 158 |
| Race/Ethnicity, Customized(Participants) | Finerenone Group | Placebo Group | Total |
|---|---|---|---|
| Pooled race — White | 85 | 90 | 175 |
| Pooled race — Asian | 23 | 25 | 48 |
| Pooled race — Black | 9 | 6 | 15 |
| Pooled race — Other | 3 | 1 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Ran from Feb 2024 to primary completion in Aug 2025, 17 months.
Results were first posted in Oct 2026, 1 year 2 months after primary completion.
Of 104 industry-sponsored phase 3 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 49. This study's 17 months is below that.
Counting every sponsor, half of 145 studies reached it within 32 months; a quarter within 19 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Finerenone
Renal Insufficiency, Chronic →